New and improved interventions are required in these rapidly expanding, yet poorly served areas of supportive care, to improve treatment outcomes and patients’ quality of life. The company addresses these areas through a process called repurposing which it defines as the discovery, development and protection of, new, differentiated indications, of existing marketed drugs. This approach allows Acacia Pharma to efficiently generate products with lower development risk, which can be brought to market more quickly and at lower cost when compared to new chemical and molecular entities. Acacia Pharma has generated a pipeline of four product opportunities, retaining commercial rights to all of them. The company’s lead project, APD421 for management of post-operative nausea and vomiting (PONV), has completed one Phase 2 and two Phase 3 studies, with further Phase 3 studies in combination prophylaxis and rescue treatment being planned. A Phase 2 dose ranging study of APD403 for CINV is ongoing, and the company has successfully completed a Phase 2 study of APD515 for xerostomia (dry mouth) in advanced cancer patients and a Phase 2a study with APD209 in cancer cachexia.